20:34 , Feb 3, 2017 |  BC Week In Review  |  Company News

Mitsubishi, Biogen deal

Mitsubishi and Biogen terminated a 2015 deal granting Biogen exclusive rights to develop and commercialize amiselimod (MT-1303) worldwide, excluding Asian territories. The small molecule sphingosine 1-phosphate (S1P) receptor functional antagonist has completed Phase II trials...
07:00 , Oct 26, 2016 |  BC Extra  |  Top Story

Biogen reports Tecfidera growth, ends S1P program

In its 3Q16 earnings report, Biogen Inc. (NASDAQ:BIIB) said sales of multiple sclerosis drug Tecfidera dimethyl fumarate grew 10% compared to 3Q15. The company also said it discontinued development of autoimmune candidate amiselimod ( MT-1303),...